{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:09Z","timestamp":1790890929816,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["GN3040"],"award-info":[{"award-number":["GN3040"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018817","name":"LUPUS UK","doi-asserted-by":"publisher","award":["R2023AU0115"],"award-info":[{"award-number":["R2023AU0115"]}],"id":[{"id":"10.13039\/501100018817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032091","name":"Royal Free Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"NIHR UCLH BRC","doi-asserted-by":"publisher","award":["BRC773\/III\/CC\/101350"],"award-info":[{"award-number":["BRC773\/III\/CC\/101350"]}],"id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Arthritis UK","doi-asserted-by":"publisher","award":["22856"],"award-info":[{"award-number":["22856"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005041","name":"Universit\u00e9 Catholique de Louvain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2025.12.011","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:01:28Z","timestamp":1768424488000},"page":"1125-1139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type I interferon endotypes drive divergent clinical trajectories in childhood-onset SLE uncovered through a novel systems immunology approach"],"prefix":"10.1016","volume":"85","author":[{"given":"Heather","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Goulden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraan","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Adeyeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy P.","family":"Ardoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Schanberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-7652","authenticated-orcid":false,"given":"George A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.12.011_bib0001","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.ard.2025.12.011_bib0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10067-022-06093-3","article-title":"Comorbidity in young patients with juvenile systemic lupus erythematosus: how can we improve management?","volume":"41","author":"Ciurtin","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.12.011_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108274","article-title":"Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options","volume":"209","author":"Smith","year":"2019","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.ard.2025.12.011_bib0004","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.12.011_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"10381","key":"10.1016\/j.ard.2025.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0007","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ard.2025.12.011_bib0008","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.12.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001032","article-title":"Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature","volume":"10","author":"Arnaud","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.ard.2025.12.011_bib0010","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/rheumatology\/keae643","article-title":"Elevated serum interferon-\u03b12 associates with activity and flare risk in Juvenile-onset Systemic Lupus Erythematosus","volume":"64","author":"Natoli","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.12.011_bib0011","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/rheumatology\/keac698","article-title":"Serum IFN\u03b12 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort","volume":"62","author":"Wahadat","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.12.011_bib0012","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/art.43227","article-title":"Genetics of childhood-onset systemic lupus erythematosus (cSLE)","volume":"77","author":"Carlomagno","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0013","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"issue":"50","key":"10.1016\/j.ard.2025.12.011_bib0014","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1073\/pnas.1814589115","article-title":"ERVmap analysis reveals genome-wide transcription of human endogenous retroviruses","volume":"115","author":"Tokuyama","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.ard.2025.12.011_bib0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using nanoString technology","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"issue":"8","key":"10.1016\/j.ard.2025.12.011_bib0016","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ard.2025.12.011_bib0017","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.12.011_bib0018","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.ard.2025.12.011_bib0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41590-025-02137-3","article-title":"IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms","volume":"26","author":"Mishra","year":"2025","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001475","article-title":"Next generation sequencing analysis reveals complex genetic architecture of childhood-onset systemic lupus erythematosus","volume":"12","author":"Lewandowski","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.ard.2025.12.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70003","article-title":"How (Ultra-)Rare gene variants improve our understanding of more common autoimmune and inflammatory diseases","volume":"7","author":"Belot","year":"2025","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.12.011_bib0023","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat Immunol"},{"issue":"6589","key":"10.1016\/j.ard.2025.12.011_bib0024","doi-asserted-by":"crossref","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ard.2025.12.011_bib0025","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ard.2025.12.011_bib0026","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"9","key":"10.1016\/j.ard.2025.12.011_bib0027","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000799","article-title":"Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study","volume":"10","author":"Wahadat","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"51","key":"10.1016\/j.ard.2025.12.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032274","article-title":"Construction of molecular subgroups in childhood systemic lupus erythematosus using bioinformatics","volume":"101","author":"Ma","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0030","article-title":"Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFN\u03b1 and B cell subsets","volume":"4","author":"Bradford","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ard.2025.12.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.ard.2025.12.011_bib0032","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ard.2025.01.025","article-title":"Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls","volume":"84","author":"Touma","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725046059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725046059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:16:14Z","timestamp":1780323374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725046059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496725046059"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.12.011","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I interferon endotypes drive divergent clinical trajectories in childhood-onset SLE uncovered through a novel systems immunology approach","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}